Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 142-153

  Bianconi, Fortunato ^a   Baldelli, Elisa ^b   Ludovini, Vienna ^b   Crinò, Lucio ^b   Flacco, Antonella ^b   Valigi, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

EGFR; IGF1R; Mathematical modeling; Survival analysis; Systems Biology; Translation Oncology

Indexed keywords

EGFR; IGF1R; MATHEMATICAL MODELING; SURVIVAL ANALYSIS; SYSTEMS BIOLOGY;

BIOLOGICAL ORGANS; CYTOLOGY; DISEASES; GENE EXPRESSION; MOLECULAR BIOLOGY; ONCOLOGY; PEPTIDES; SENSITIVITY ANALYSIS;

ORDINARY DIFFERENTIAL EQUATIONS;

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN C;

CANCER; GENE EXPRESSION; HYBRIDIZATION; IMMUNOASSAY; IN SITU MEASUREMENT; MOLECULAR ANALYSIS; NUMERICAL MODEL; PROTEIN; SENSITIVITY ANALYSIS; SURVIVAL;

ARTICLE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSLATIONAL RESEARCH;

CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84855725908     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.05.010     Document Type: Article

References (47)

1. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic pi3k deregulates transcription and translation. Nat Rev Cancer 2005, 5(12):921-929.
2. Becker M.A., Yee D. Egfr signaling networks in cancer therapy (chapter 11). Business 2008, 155-168.
3. Bianconi F. Dynamic modeling, parameter estimation and experiment design in Systems Biology with applications to Oncology. Ph.D. thesis 2010, University of Perugia.
4. Bianconi F., Lillacci G., Valigi P. Dynamic modeling and parameter identification for biological networks: application to the DNA damage and repair processes. Handbook of research on computational and systems biology: interdisciplinary applications 2010, L.A. Liu, D. Wei, Y. Li (Eds.).
5. Blakesley V., Stannard B., Kalebic T., et al. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997, 152:339-344.
6. Boguski M., McCormick F. Proteins regulating ras and its relatives. Nature 1993, 366(6456):643-654.
7. Brown K.S., Hill C.C., Calero G.a., Myers C.R., Lee K.H., Sethna J.P., et al. The statistical mechanics of complex signaling networks: nerve growth factor signaling. Physical Biology 2004, 1(3-4):184-195.
8. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ERBB-2 and erbb-3. Experimental Cell Research 2003, 284(1):54-65.
9. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C., Forbes B.E. Molecular interactions of the IGF system. Cytokine & Growth Factor reviews 2005, 16(4-5):421-439.
10. Dong Chen, Waters S.B., Holt K.H., Pessin J.E. Sos phosphorylation and disassociation of the grb2-sos complex by the erk and jnk signaling pathways. The Journal of biological chemistry 1996, 271(11):6328-6332.
11. Dufourny B., Alblas J., vanTeeffelen H., et al. Mitogenic signaling of insulin-like growth factor i in mcf-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997, 272:31163-31171.
12. Dziadziuszko R., Merrick D., Witta S., Mendoza A., Szostakiewicz B., Szymanowska A., et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between igf1r fluorescent in situ hybridization, protein expression, and mrna expression. J Clin Onco 2010, 28(13):2174-2180.
13. Frödin M., Gammeltoft S. Role and regulation of 90 kda ribosomal s6 kinase (rsk) in signal transduction. Molecular and Cellular Endocrinology 1999, 151(1-2):6.
14. Gary L., Johnson R.L. Mitogen-activated protein kinase pathways mediated by erk, jnk, and p38 protein kinases. Science 2002, 298(5600):1911-1912.
15. Gong Y., Yao E., Shen R., Goel A., Arcila M., Teruya-Feldstein J., et al. High expression levels of total igf-1r and sensitivity of nsclc cells in vitro to an anti-igf-1r antibody (r1507). PloS one 2009, 4(10):e7273.
16. Gonzalez-Angulo A.M., Hennessy B.T.J., Mills G.B. Future of personalized medicine in oncology: A systems biology approach. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010, 28(16):2777-2783.
17. Gualberto A., Dolled-Filhart M., Gustavson M., Christiansen J., Wang Y., Hixon M., et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor i receptor inhibition. Clin Cancer Res 2010, 16(18):4654-4665.
18. Guan K.L., Figueroa C., Brtva T.R., Zhu T., Taylor J., Barber T.D., et al. Negative regulation of the serine/threonine kinase b-raf by akt. The Journal of Biological Chemistry 2000, 275(35):27354-27359.
19. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the pi3k/akt pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988-1004.
20. Hindmarsh A.C., Brown P.N., Grant K.E., Lee S.L., Serban R., Shumaker D.E., et al. Sundials: suite of nonlinear and differential/algebraic equation solvers. ACM Trans Math Softw 2005, 31(3):363-396.
21. Jiang Y., Rom W.N., Yie T.a., Chi C.X., Tchou-Wong K.M. Induction of tumor suppression and glandular differentiation of a549 lung carcinoma cells by dominant-negative igf-i receptor. Oncogene 1999, 18(44):6071-6077.
22. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16(1):3-34.
23. Khandwala H., McCutcheon I., Flyvbjerg A., Friend K. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000, 21:215-244.
24. Kim E.K., Choi E.J. Pathological roles of mapk signaling pathways in human diseases. Biochimica et Biophysica Acta 2010, 1802(4):396-405.
25. Lazebnik Y. Can a biologist fix a radio? - or, what I learned while studying apoptosis. Cancer cell 2002, 2(3):179-182.
26. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor i receptor. Endocr Rev 1995, 16(2):143-163.
27. López-Calderero I., Chávez E.S., García-Carbonero R. The insulin-like growth factor pathway as a target for cancer therapy. Clinical and Translational Oncology 2010, 12(5):326-338.
28. Ludovini V., Bellezza G., Pistola L., Bianconi F., Di Carlo L., Sidoni a., et al. High co-expression of both insulin-like growth factor receptor-1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Annals of Oncology: official Journal of the European Society for Medical Oncology/ESMO 2009, 20(5):842-849.
29. Ludovini V., Bianconi F., Pistola L., Chiari R., Minotti V., Colella R., et al. Phosphoinositide-3-kinase catalytic alpha and kras mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, Epub ahead of print.
30. Markevich N.I., Hoek J.B., Kholodenko B.N. Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. The Journal of Cell Biology 2004, 164(3).
31. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33(4):369-385.
32. Mitsudomi T., Yatabe Y. Epidermal growth factor receptor in relation to tumor development: Egfr gene and cancer. FEBS J 2010, 277(2):301-308.
33. Orton R.J., Adriaens M.E., Gormand A., Sturm O.E., Kolch W., Gilbert D.R. Computational modelling of cancerous mutations in the egfr/erk signalling pathway. BMC Syst Biol 2009, 3:100.
34. Pearson G. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22(2):153-183.
35. Qi M., Elion E.a. Map kinase pathways. Journal of cell science 2005, 118(Pt 16):3569-3572.
36. Riedemann J., Macaulay V.M. Igf1r signalling and its inhibition. Endocrine-related cancer 2006, 13(Suppl 1):S33-S43.
37. Roberts P.J., Der C.J. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310.
38. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical Cancer Research 2006, 12(18):5268-5272.
39. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of egf receptor. Cell 2002, 110(6):669-672.
40. Schubbert S., Shannon K., Bollag G. Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7(4):295-308.
41. Shane Donovana K.M.S., Bollagb G. Gtpase activating proteins: critical regulators of intracellular signaling. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2002, 1602(1):23-45.
42. Varella-Garcia M., Diebold J., Eberhard D.A., Geenen K., Hirschmann A., Kockx M., et al. Egfr fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. Journal of Clinical Pathology 2009, 62(11):970-977.
43. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase-akt pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501.
44. Yarden Y. The egfr family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European journal of cancer 2001, 37(Suppl 4):S3-S8. (Oxford, England: 1990).
45. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.
46. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19(10):2013-2023.
47. Zielinski R., Przytycki P., Zheng J., Zhang D., Przytycka T., Capala J. The crosstalk between egf, igf, and insulin cell signaling pathways - computational and experimental analysis. BMC Syst Biol 2009, 3(1):88. Crosstalk between EGF, IGF.